Literature DB >> 7547105

Enteropathic arthritis, Whipple's disease, juvenile spondyloarthropathy, uveitis, and SAPHO syndrome.

M Leirisalo-Repo1.   

Abstract

During the past year, concepts of spondyloarthropathy and associated gut abnormalities have been further confirmed. In addition, the evolution of spondyloarthropathy to ankylosing spondylitis seems to be determined by the underlying gut inflammation. Other factors present early in spondyloarthropathy that affect the long-term prognosis of the disease have been determined. HLA-B27 has an impact on the severity of spondyloarthropathy. Its presence is also highly associated with uveitis. Paradoxically, HLA-B27+ uveitis is usually benign, with a good prognosis. A subgroup of patients can, however, have severe posterior uveitis; immunosuppressive drugs have been used to treat this disorder.

Entities:  

Mesh:

Year:  1995        PMID: 7547105     DOI: 10.1097/00002281-199507000-00004

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  4 in total

1.  IgA autoreactivity: a feature common to inflammatory bowel and connective tissue diseases.

Authors:  L Kazemi-Shirazi; C H Gasche; S Natter; A Gangl; J Smolen; S Spitzauer; P Valent; D Kraft; R Valenta
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

2.  Ocular presentation of the SAPHO syndrome.

Authors:  M Smith; A Buller; R Radford; R Laitt; B Leatherbarrow
Journal:  Br J Ophthalmol       Date:  2005-08       Impact factor: 4.638

3.  Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history.

Authors:  T R Orchard; B P Wordsworth; D P Jewell
Journal:  Gut       Date:  1998-03       Impact factor: 23.059

4.  Chronic non-bacterial osteomyelitis in children.

Authors:  H J Girschick; P Raab; S Surbaum; A Trusen; S Kirschner; P Schneider; T Papadopoulos; H K Müller-Hermelink; P E Lipsky
Journal:  Ann Rheum Dis       Date:  2005-02       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.